Medite Cancer Diagnostics, Inc. (MDIT)
Medite Cancer Diagnostics, Inc. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Orlando, FL, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $8,672. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -100.0%. Its beta of 8.97 implies it has historically moved more than the broad market.
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
Medite Cancer Diagnostics, Inc. is most often compared with the following Healthcare names: